Krishna Institute of Medical Sciences Limited — PPTs, 06-08-2025: Investor Presentation

**1. Financial Highlights:**

Revenue grew 26.8% YoY to ₹878.7 Cr, but EBITDA margin contracted to 22.7% (from 26.6% YoY), leading to a 10.7% YoY decline in net profit (₹85 Cr) and 9.2% EPS drop, despite EBITDA rising 8.5%. Operational volumes (IP/OP) and average revenue metrics (ARPOB/ARPP) all posted strong double-digit YoY growth, though occupancy declined to 48.8% due to expanded capacity.

**2. Strategic Initiatives & Growth Drivers:**

KIMS is aggressively expanding, with new bed capacity planned across Bangalore (800 beds), Ongole, Anantapur, Kondapur, and Rajahmundry through FY27. Investments continue in advanced medical technology, including new robotic surgical systems.

**3. Business Developments:**

KIMS Hospitals Thane (300 beds) and 20 new beds in Kondapur became operational this quarter, significantly boosting capacity. Clinical advancements include the first pediatric liver transplant in Nashik.

**4. Market Position & Competitive Advantage:**

KIMS maintains a strong market position, leading in specialities like organ transplantation, nephrology, and neurosurgery in Andhra Pradesh (per CRISIL 2021). Its strategy prioritizes doctor partnerships, affordable care, and modern infrastructure.

**5. Investor Implications:**

While new facility ramp-up, particularly in Maharashtra, pressured margins and profits, the aggressive expansion pipeline signals significant future growth potential. Investors should monitor efficient stabilization of new units for sustained profitability.